Effectiveness of and Implementation Strategies for 'Disfrutando'.
Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Jun 10, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a program called "Disfrutando" designed to help people prevent and manage type 2 diabetes, a common condition that affects how your body controls blood sugar. The study focuses on not only teaching people about managing their diabetes but also addressing social challenges—like access to healthy food or safe places to exercise—that can make it harder to stay healthy. The goal is to find practical ways to support people living with or at risk for type 2 diabetes.
To take part, individuals need to be between 65 and 74 years old and have a blood test called Hemoglobin A1C at 5.7 or higher, which shows higher blood sugar levels and a risk for diabetes. People with lower blood sugar levels (A1C of 5.6 or less) cannot join. While the study is not recruiting yet, participants can expect to engage with the "Disfrutando" program, which aims to help them improve their health by learning self-care skills and overcoming everyday barriers to healthy living. This trial includes men and women and hopes to make managing diabetes easier and more effective for those involved.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hemoglobin A1C of 5.7 or higher
- Exclusion Criteria:
- • Hemoglobin A1C of 5.6 or lower
About University Of Missouri Columbia
The University of Missouri-Columbia is a leading academic institution dedicated to advancing medical research and clinical innovation. As a prominent sponsor of clinical trials, the university leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving patient outcomes across a variety of health conditions. With a commitment to ethical research practices and collaboration with multidisciplinary teams, the University of Missouri-Columbia strives to translate scientific discoveries into effective therapeutic interventions, ultimately enhancing the quality of care in the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported